AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line Setting THOUSAND OAKS, Calif., Aug. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today...

Click to view original post